Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

Stopped early · Phase 2/Phase 3

Conditions studied: HIV Infections

In brief

Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often included as part of patients' treatment, but many HIV-infected patients develop resistance to commonly used NRTIs such as lamivudine (3TC) and emtricitabine (FTC). This study will examine whether including apricitabine as part of patients' treatment is more effective than including lamivudine,when patients change treatment because of drug resistance.

Key facts

Study ID

NCT00612898

Run by

Avexa

People needed

239

Starts

2008-02-01

Expected to finish

2010-01-01

Last updated by the study team

2012-01-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-1 positive with M184V/I mutation in reverse transcriptase;
• 18 years of age or older;
• Currently taking lamivudine (3TC) or emtricitabine (FTC)

You may not qualify if…

• Female patients who are pregnant or breastfeeding;
• Current hepatitis B virus (HBV) infection;
• Current treatment for hepatitis C virus infection;
• Renal function not adequate

Where it is running

• Living Hope Clinical Foundation, Inc — Long Beach, California, United States
• Kaiser Permanente Medical Center — San Francisco, California, United States
• AIDS Research Alliance — West Hollywood, California, United States
• Denver Health & Hospital Authority — Denver, Colorado, United States
• Georgetown University — Washington D.C., District of Columbia, United States
• George Washington University — Washington D.C., District of Columbia, United States
• Gary Richmond, MD — Fort Lauderdale, Florida, United States
• Orlando Immunology Center — Orlando, Florida, United States
• Infectious Disease Research Institute, Inc — Tampa, Florida, United States
• Treasure Coast Infectious Diseases Consultants — Vero Beach, Florida, United States
• Aids Research Consortium Of Atlanta Inc. — Atlanta, Georgia, United States
• Atlanta Infectious Disease Group, PC — Atlanta, Georgia, United States
• University of Hawaii — Honolulu, Hawaii, United States
• Northwestern University — Chicago, Illinois, United States
• University of Kansas School of Medicine — Wichita, Kansas, United States
• Fenway Community Health Center — Boston, Massachusetts, United States
• Community Research Intiative of New England — Boston, Massachusetts, United States
• I.D. Care, Inc. — Hillsborough, New Jersey, United States
• Saint Michael's Medical Center — Newark, New Jersey, United States
• Summa Health System — Akron, Ohio, United States
• The Research & Education Institute — Portland, Oregon, United States
• Central Texas Clinical Research — Austin, Texas, United States
• Nicholaos C Bellos, MD, PA — Dallas, Texas, United States
• North Texas Infectious Diseases Consultants, P.A. — Dallas, Texas, United States
• Southwest Center for HIV/AIDS — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.